Teva Pharmaceutical Industries EVP, Europe Commercial Richard Daniell Sells $1.93M of Stock
Richard Daniell, EVP, Europe Commercial, sold 45,003 shares of Teva Pharmaceutical Industries Ltd at $42.80 to $42.91 a share (average $42.86) in 2 transactions, worth $1.93M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 55,755 (-26.4%).
Teva Pharmaceutical Industries President and CEO Richard D. Francis Sells $10.6M of Stock
Richard D. Francis, President and CEO, sold 250,000 shares of Teva Pharmaceutical Industries Ltd at $42.24 a share, worth $10.6M in total on Nov 10, 2026. Shares held after the trade: 927,529 (-21.2%).
Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.97M of Stock
Mark Sabag, See "Remarks", sold 44,710 shares of Teva Pharmaceutical Industries Ltd at $44.14 a share, worth $1.97M in total on Nov 12, 2026. Shares held after the trade: 80,760 (-35.6%).
Teva Pharmaceutical Industries CAO Amir Weiss Sells $744K of Stock
Amir Weiss, CAO, sold 17,289 shares of Teva Pharmaceutical Industries Ltd at $43.03 to $43.15 a share (average $43.04) in 3 transactions, worth $744K in total on Nov 9, 2026. Shares held after the trade: 3,537 (-72.9%).
Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.93M of Stock
Mark Sabag, See "Remarks", sold 46,000 shares of Teva Pharmaceutical Industries Ltd at $41.93 a share, worth $1.93M in total on Nov 5, 2026. Shares held after the trade: 80,760 (-36.3%).
Dov Bergwerk, Interim Cheif Legal Officer, sold 26,260 shares of Teva Pharmaceutical Industries Ltd at $41.72 a share, worth $1.1M in total on Nov 4, 2026. Shares held after the trade: 11,943 (-42.3%).
Teva is successfully transitioning to a biopharma model, raising 2026 revenue guidance to $16.7B-$17B and achieving investment-grade status while scaling innovative products like Austedo and Uzedy.
Teva Pharmaceutical Industries reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year due to competition for its generic Revlimid, offset by 33% growth in its innovative brand portfolio. The company raised its full-year 2026 revenue outlook for key brands AUSTEDO, AJOVY, and UZEDY following strong quarterly performance and gross margin expansion.
Term
Q3 2026
“Teva’s Pivot to Growth strategy is delivering strong results, as evidenced by the 33% growth across our key innovative brands and the substantial expansion of our non-GAAP gross profit margin to its highest level in a decade. We are strengthening our neuroscience leadership with the launch of WELTRUZA™ and the strategic addition of BXCL-501, while our biosimilars business is set to achieve its 2027 revenue goal a year ahead of schedule.”
Teva Pharmaceutical Industries appointed Dr. David J. Brailer to its Board of Directors, effective November 3, 2026. Dr. Brailer, an independent director with extensive health-tech and policy experience, will serve on the Human Resources and Compensation and Compliance Committees until the 2027 annual meeting.
Teva Pharmaceutical Industries $3.2B Debt Financing with The Bank of New York Mellon
Teva Pharmaceutical Industries issued a multi-tranche series of senior notes totaling $3.2 billion in USD-denominated notes and €1.5 billion in Euro-denominated notes. The proceeds are intended to fund the redemption of existing debt and for general corporate purposes, effectively refinancing the company's debt maturity profile.
Teva Pharmaceutical Industries Ltd. has transitioned its listing on the New York Stock Exchange from American depositary shares (ADSs) to ordinary shares under the existing ticker 'TEVA'. The company's ADS program was terminated effective September 14, 2026, with each ADS exchanged for one ordinary share on a one-for-one basis.